Medeva Changes Tack
Executive Summary
Criticized for not properly managing growth, Medeva's managers contend they're building a sustainable business. They used profits from methylphenidate, an off-patent treatment for attention deficit disorder, to finance a long list of acquisitions, many of which didn't work out. When methylphenidate sales crashed with the entrance of generic competition, so did Medeva's credibility with investors. They're hoping their self-sustaining European and American infrastructure will help them attract the higher-risk, higher profit products they shunned in their original strategy but now need in order to dig themselves out of their profit hole.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.